Repligen (NASDAQ:RGEN) Upgraded to Strong-Buy at Hsbc Global Res

Hsbc Global Res upgraded shares of Repligen (NASDAQ:RGEN) to a strong-buy rating in a research report released on Wednesday morning,Zacks.com reports.

Several other research analysts also recently issued reports on the stock. Barclays upped their price target on shares of Repligen from $150.00 to $160.00 and gave the stock an “overweight” rating in a report on Thursday. HC Wainwright reiterated a “buy” rating and set a $180.00 price target on shares of Repligen in a report on Wednesday, September 3rd. Wells Fargo & Company lowered their price target on shares of Repligen from $180.00 to $175.00 and set an “overweight” rating for the company in a report on Wednesday, July 30th. Royal Bank Of Canada reissued an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a research note on Tuesday, September 2nd. Finally, Jefferies Financial Group reduced their price objective on shares of Repligen from $145.00 to $135.00 and set a “hold” rating on the stock in a research note on Friday, September 12th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $168.08.

Repligen Stock Down 0.4%

Shares of RGEN opened at $145.23 on Wednesday. Repligen has a one year low of $102.96 and a one year high of $182.52. The company has a market cap of $8.17 billion, a P/E ratio of -580.90, a P/E/G ratio of 2.69 and a beta of 1.08. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. The firm has a 50 day simple moving average of $121.84 and a two-hundred day simple moving average of $125.49.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.03). The firm had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The firm’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Research analysts forecast that Repligen will post 1.72 EPS for the current fiscal year.

Insiders Place Their Bets

In other Repligen news, Director Martin D. Madaus purchased 1,800 shares of the firm’s stock in a transaction on Friday, August 8th. The stock was purchased at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the acquisition, the director owned 1,800 shares in the company, valued at approximately $201,834. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.20% of the company’s stock.

Institutional Trading of Repligen

Large investors have recently bought and sold shares of the business. Twin Tree Management LP acquired a new stake in Repligen during the 1st quarter worth about $29,000. Hantz Financial Services Inc. boosted its position in shares of Repligen by 2,663.6% during the 2nd quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 293 shares in the last quarter. Signaturefd LLC boosted its position in shares of Repligen by 65.3% during the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 128 shares in the last quarter. Center for Financial Planning Inc. boosted its position in shares of Repligen by 110.3% during the 1st quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 193 shares in the last quarter. Finally, UMB Bank n.a. boosted its position in shares of Repligen by 99.4% during the 1st quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 332 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.